Study Title
Takeda 204
Purpose
To assess the safety and effectiveness of treatment with daily oral administration of dexlansoprazole delayed release capsules (15,30, and 60 mg) in pediatric subjects aged 1 to 11 years with symptomatic nonerosive GERD.
Eligibility
Pediatric Subjects Aged 1 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease
Study Process
Subjects 1-11 years old with symptomatic Nonerosive GERD will be enrolled in the study. Subjects will undergo an Endoscopy and will have lab tests at most visits
Trial Details
Investigator:
Sunny Hussain, M.D.
IRB:
Willis-Knighton
IRB Number:
Trial Type:
Drug
Sponsor:
Takeda
Contact Information:
(318) 212-8130
http://www.wkpgis.com